Motor unit number index (MUNIX) in the D50 disease progression model reflects disease accumulation independently of disease aggressiveness in ALS.

Autor: Ebersbach T; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany., Roediger A; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany. annekathrin.roediger@med.uni-jena.de., Steinbach R; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany., Appelfeller M; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany., Tuemmler A; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany., Stubendorff B; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany., Schuster S; Precision Neurology, University of Lübeck, Lübeck, Germany., Herdick M; Precision Neurology, University of Lübeck, Lübeck, Germany., Axer H; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany., Witte OW; Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.; Center for Healthy Ageing, Jena University Hospital, Jena, Germany., Grosskreutz J; Precision Neurology, University of Lübeck, Lübeck, Germany.; Center for Healthy Ageing, Jena University Hospital, Jena, Germany.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Sep 26; Vol. 12 (1), pp. 15997. Date of Electronic Publication: 2022 Sep 26.
DOI: 10.1038/s41598-022-19911-0
Abstrakt: The neurophysiological technique motor unit number index (MUNIX) is increasingly used in clinical trials to measure loss of motor units. However, the heterogeneous disease course in amyotrophic lateral sclerosis (ALS) obfuscates robust correlations between clinical status and electrophysiological assessments. To address this heterogeneity, MUNIX was applied in the D50 disease progression model by analyzing disease aggressiveness (D50) and accumulation (rD50 phase) in ALS separately. 237 ALS patients, 45 controls and 22 ALS-Mimics received MUNIX of abductor pollicis brevis (APB), abductor digiti minimi (ADM) and tibialis anterior (TA) muscles. MUNIX significantly differed between controls and ALS patients and between ALS-Mimics and controls. Within the ALS cohort, significant differences between Phase I and II revealed in MUNIX, compound muscle action potential (CMAP) and motor unit size index (MUSIX) of APB as well as in MUNIX and CMAP of TA. For the ADM, significant differences occurred later in CMAP and MUNIX between Phase II and III/IV. In contrast, there was no significant association between disease aggressiveness and MUNIX. In application of the D50 disease progression model, MUNIX can demonstrate disease accumulation already in early Phase I and evaluate effects of therapeutic interventions in future therapeutic trials independent of individual disease aggressiveness.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje